Results 71 to 80 of about 10,858 (213)

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system

HIV Medicine, EarlyView.
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Leidan Zhang, Ling Chen, Jia Tang, Xiaosheng Liu, Liyuan Zheng, Fada Wang, Xin Huang, Wei Cao, Taisheng Li   +8 more
wiley   +1 more source

Bone mineral density optimisation in adults with perinatally acquired HIV infection in routine care [PDF]

, 2017
We report on BMD and factors associated with reductions in BMD for all adults with perinatally acquired HIV who attended a London clinic between May 2014 and October 2016.
Fidler, S, Foster, C, Fyles, F, Pasvol, TJ   +3 more
core  

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles [PDF]

Clinical and Molecular Hepatology, 2022
Hung-Yao Lin, Tai-Chung Tseng
doaj   +1 more source

Fanconi Syndrome Due to Tenofovir Disoproxil Fumarate in a Patient with Chronic Hepatitis B Induced Cirrhosis: A Case Report

Case Reports in Clinical Practice
We present a 63-year-old woman with chronic hepatitis B. The patient has a history of cirrhosis due to chronic hepatitis B and is under treatment with Tenofovir disoproxil fumarate.
Milad Khodabakhshi, Behshad Pazooki
doaj   +1 more source

Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof‐of‐Concept Study

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
Neglected tropical diseases (NTDs) remain a major global health challenge, particularly in low‐ and middle‐income countries. Kinetoplastid parasites causing Chagas disease, leishmaniasis, and African trypanosomiasis rely on host purine salvage pathways, making nucleoside analogues attractive therapeutic candidates.
Silvester Lowe, Vishal Satikuvar, Tanjia M. Syeda, Monica Cal, Pascal Mäser, Marcel Kaiser, Hachemi Kadri   +6 more
wiley   +1 more source

2016 Pipeline Report HIV and TB [PDF]

, 2016
HIV and TB: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in ...
Erica Lessem, Lindsay McKenna, Mark Harrington, Mike Frick, Polly Clayden, Richard Jefferys, Simon Collins, Tim Horn   +7 more
core  

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe [PDF]

, 2018
Background: HBsAg immune-escape mutations can favor HBV-transmission also in vaccinated individuals, promote immunosuppression-driven HBV-reactivation, and increase fitness of drug-resistant strains.
Alvarez, M.R. (Marta), Ben Ari, Z. (Ziv), Boland, G.J. (Greet), Boucher, C.A.B. (Charles), Bruzzone, B. (Bianca), Colagrossi, L. (Luna), Coppola, N. (Nicola), Di Carlo, D., Dyda, T. (Tomasz), Garcia, F. (Federico), Hermans, L.E. (Lucas Etienne), Kaiser, R. (Rolf), Krarup, H.B. (H.), Köse, S. (Sukran), Lazarevic, I. (Ivana), Lepej, S.Z. (Snjezana), Lunar, M.M. (Maja M.), Maylin, S. (Sarah), Micheli, V. (Valeria), Mor, O. (Orna), Paraschiv, C. (Corina), Paraskevis, D. (Dimitrios), Pas, S.D. (Suzan), Perno, C.F. (Carlo), Poljak, M. (Mario), Puchhammer-Stöckl, E. (Elisabeth), Salpini, R. (Romina), Seguin-Devaux, C., Simon, F. (François), Stanojevic, M. (Maja), Stene-Johansen, K. (Kathrine), Svicher, V. (Valentina), Tihic, N. (Nijaz), Trimoulet, P. (Pascale), Verheyen, J. (Jens), Vince, A. (Adriana), Weis, N. (Nina), Wensing, A. (Amj), Yalcinkaya, T. (Tülay)   +38 more
core   +2 more sources

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 8, Page 1089-1098, April 2026.
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka   +6 more
wiley   +1 more source

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir [PDF]

, 2016
OBJECTIVE: Atazanavir (ATV) and lopinavir (LPV) have been associated with kidney disease progression in HIV positive patients, with no data reported for darunavir (DRV).
Chadwick, D, Hamzah, L, Jones, R, Jose, S, Nelson, M, Phillips, A, Post, FA, Sabin, CA, Trevelion, R, Williams, DI   +9 more
core   +2 more sources